Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

NCT07211178 · clinicaltrials.gov ↗

RECRUITING

Status

900

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
TNBC - Triple-Negative Breast Cancer
HR Positive/HER-2 Negative Breast Cancer
HER2 + Breast Cancer
Early Stage Breast Cancer

Interventions

OTHER: There are no interventions in this observational study.

Sponsor

Tempus AI